<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437775</url>
  </required_header>
  <id_info>
    <org_study_id>167/06</org_study_id>
    <nct_id>NCT00437775</nct_id>
  </id_info>
  <brief_title>ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects</brief_title>
  <official_title>Angiotensin Converting Enzyme Inhibitors &amp; Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      Proteinuria is an expression of diabetic nephropaty in type 1 and type 2 patients.
      Hypertenshion treatment and decreasing urine protein excretion, slow down renal
      deterioration. Treating diabetic ,hypertensive patients with Angiotensin Converting Enzyme
      inhibitors (ACEi), Angiotensin receptor blockers (ARBs)is common practice. The aim of our
      work is to examine 1.The prevalence of ACE and ARB treatment in diabetic patients with or
      without hypertension.2. Adverse drug reactions of ACEi and ARBs alone or in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study group- men and women with diabetes mellitus type 2,who were hospitalized in the
      department of internal medicine in Assaf- Harofeh Medical Center.

      During hospitalization, data regarding the clinical history,chronic diseases and drugs were
      collected from the medical files. Blood tests results were recorded during hospitalization
      .The patients were asked about adverse drug effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date>March 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients admitted to department of Internal Medicine in Assaf Harofeh
             Medical Center

        Exclusion Criteria:

          -  Type 1 diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahuva Golik, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Sackler School of Medicine, Tel-Aviv University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alina Alperovich, B.Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lila Akivison, MSc.Pharm</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sofia Berkovitch, MSc. Pharm</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabby Elbaz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf- Hrofech Medical Senter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alina Alperovich, B.Pharm</last_name>
    <phone>972-547616736</phone>
    <email>golik@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabby Elbaz, MD</last_name>
    <phone>972-8-977-9240</phone>
    <email>golik@asaf.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Alperovich, B.Pharm</last_name>
      <phone>972-547616736</phone>
      <email>golik@asaf.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care. 2006 Oct;29(10):2210-7.</citation>
    <PMID>17003295</PMID>
  </results_reference>
  <results_reference>
    <citation>Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm. 2006 May;12(4):303-9.</citation>
    <PMID>16792436</PMID>
  </results_reference>
  <results_reference>
    <citation>Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006 Jan;24(1):11-25. Review.</citation>
    <PMID>16331093</PMID>
  </results_reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>February 20, 2007</last_update_submitted>
  <last_update_submitted_qc>February 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2007</last_update_posted>
  <keyword>Diabetes Mellitus type 2</keyword>
  <keyword>ACE Inhibitors</keyword>
  <keyword>ARBs</keyword>
  <keyword>Adverse drug effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

